Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-072367
Filing Date
2025-05-15
Accepted
2025-05-15 14:00:35
Documents
106
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q jagx-20250331.htm   iXBRL 10-Q 4594491
2 EX-10.3 jagx-ex10_3.htm EX-10.3 21300
3 EX-31.1 jagx-ex31_1.htm EX-31.1 17660
4 EX-31.2 jagx-ex31_2.htm EX-31.2 17656
5 EX-32.1 jagx-ex32_1.htm EX-32.1 9849
6 EX-32.2 jagx-ex32_2.htm EX-32.2 9852
  Complete submission text file 0000950170-25-072367.txt   20699349

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT jagx-20250331.xsd EX-101.SCH 2379376
109 EXTRACTED XBRL INSTANCE DOCUMENT jagx-20250331_htm.xml XML 4730249
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36714 | Film No.: 25951295
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)